Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
Christian Dominik Fingas, Jan Best, Jan‐Peter Sowa, Ali Canbay – 30 November 2016
How does the microbiome affect liver disease?
Herbert Tilg, Christoph Grander, Alexander R. Moschen – 30 November 2016
Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
Christian Dominik Fingas, Jan Best, Jan‐Peter Sowa, Ali Canbay – 30 November 2016
Novel treatments in primary sclerosing cholangitis
Ahmad H. Ali, Keith D. Lindor – 30 November 2016
Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis
Marco Carbone, Pietro Invernizzi – 30 November 2016
The scope of hepatology practice outside the traditional academic medical center
Marcelo Kugelmas, Mitchell Shiffman – 30 November 2016
Cystic Fibrosis–Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology
Romina Fiorotto, Mario Strazzabosco – 30 November 2016
Disability in patients with end‐stage liver disease: Results from the functional assessment in liver transplantation study
Mariya L. Samoylova, Kenneth E. Covinsky, Marta Haftek, Selena Kuo, John P. Roberts, Jennifer C. Lai – 24 November 2016 – Cirrhosis leads to sarcopenia and functional decline that can severely impact one's ability to function at home and in society. Self‐reported disability scales to quantify disability—Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)—are validated to predict mortality in older adults.
Anti‐inflammatory signaling during ex vivo liver perfusion improves the preservation of pig liver grafts before transplantation
Davide Ghinolfi, Laura Caponi, Lorella Marselli, Daniele Pezzati, Maria Franzini, Paolo De Simone, Vanna Fierabracci, Piero Marchett, Aldo Paolicchi, Franco Filipponi – 24 November 2016
Reply
Marco Laudo, Matteo Ravaioli, Gaetano Manna, Giorgia Comai, Matteo Cescon, Massimo Gaudio, Valentina Bertuzzo, Chiara Zanfi, Alessandro Cucchetti, Antonio Daniele Pinna – 24 November 2016